Long-term efficacy and safety of the GLP-1 receptor agonist liraglutide in Japanese patients with type 2 diabetes mellitus.

Long-term efficacy and safety of the GLP-1 receptor agonist liraglutide in Japanese patients with type 2 diabetes mellitus. - Long-term efficacy and safety of the GLP-1 receptor agonist liraglutide in Japanese patients with type 2 diabetes mellitus.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037603

Enrollment

1000

Registered

2019-08-06

Start date

2019-05-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes Administration of liraglutide

Exclusion criteria

Exclusion criteria: Participation in the study is judged by the investigator or sub-investigator as inappropriate for any other reason

Design outcomes

Primary

Measure	Time frame
The change in the eGFR slope and urine albumin creatinine ratio	—

Secondary

Measure	Time frame
Metabolic marker; HbA1c and body weight Hemodynamic marker; systolic and diastolic blood pressure, and heart rate Liver enzyme marker; AST, ALT and gamma-GTP Liver fibrosis marker; Fib-4 index Arteriosclerosis marker; IMT and PWV Safety marker; incidence rate of Hypoglycemia	—

Countries

Japan

Contacts

Public ContactKensuke Ofuchi

Nakakinen clinic Department of clinical research

k-ofuchi@kensei-kai.com029-353-2800

Outcome results